TickerFacts.

Cue Biopharma, Inc. (CUE): Revenue

Annual figures by period end, from SEC filings.

$27.47M
Year ended 2025-12-31
$37.66M
Trailing 12 months to 2026-06-30
+180.5%
3-year compound annual growth
+54.2%
5-year compound annual growth
2018-12-31: $1.14M2019-12-31: $3.46M2020-12-31: $3.15M2021-12-31: $14.94M2022-12-31: $1.25M2023-12-31: $5.49M2024-12-31: $9.29M2025-12-31: $27.47M$27.47M
2018-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$27.47M+195.7%2026-03-16, From 2025-01-01
2024-12-31$9.29M+69.2%2026-03-16, From 2024-01-01
2023-12-31$5.49M+341.0%2025-03-31, From 2023-01-01
2022-12-31$1.25M-91.7%2024-03-28, From 2022-01-01
2021-12-31$14.94M+373.7%2023-03-21, From 2021-01-01
2020-12-31$3.15M-8.8%2022-03-16, From 2020-01-01
2019-12-31$3.46M+202.7%2021-03-09, From 2019-01-01
2018-12-31$1.14Mn/a2020-03-12, From 2018-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Cue Biopharma, Inc. (CUE)2025-12-31$27.47M+195.7%
Celularity Inc (CELU)2025-12-31$26.55M-51.0%
Entrada Therapeutics, Inc. (TRDA)2025-12-31$25.42M-87.9%
Foghorn Therapeutics Inc. (FHTX)2025-12-31$30.91M+36.8%
Verastem, Inc. (VSTM)2025-12-31$30.91M+209.1%
Alumis Inc. (ALMS)2025-12-31$24.05Mn/a
Zomedica Corp. (ZOMDF)2025-12-31$32.03M+17.4%
NewAmsterdam Pharma Co N.V. (NAMS)2025-12-31$22.50M-50.6%
Bioharvest Sciences Inc. (BHST)2025-12-31$34.51M+37.0%

Compare CUE, CELU, TRDA, FHTX side by side · Screen every company in Pharmaceutical Preparations ↗